Sernova (TSE:SVA) has released an update.
Sernova Corp., a clinical-stage biotech firm, will be featured at the Cell & Gene Meeting on the Mesa where CEO Jonathan Rigby will present advances in cell therapy, including their ongoing diabetes clinical trial and collaborative pre-clinical work for a potential diabetes cure. The company is known for developing the Cell Pouch Transplant System aiming to provide a ‘functional cure’ for diabetes and other chronic diseases through cell therapy.
For further insights into TSE:SVA stock, check out TipRanks’ Stock Analysis page.
